Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering exits manufacturing consent decree

Executive Summary

Schering-Plough's petition to dissolve the manufacturing consent decree it has been operating under since May 2002 is granted by U.S. District Court for New Jersey. The company completed the requisite 212 significant steps and 30 validation actions to comply with current good manufacturing practices at the end of 2005 (1"The Pink Sheet" Jan. 09, 2006, In Brief). FDA did not oppose the company's petition, according to Schering...

You may also be interested in...



Schering back in good graces

Schering-Plough completed all 212 significant steps and 30 validation actions required under its manufacturing consent decree by its deadline of Dec. 31, 2005. The goal was reached on time, as the company had anticipated (1"The Pink Sheet" Nov. 14, 2005, p. 28). The consent decree's obligations and requirements are subject to certification by an external third party and review and approval by FDA...

Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.

China VBP, Localization And Other Strategies - How Far And Which Way?

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048656

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel